BACKGROUND: Acute cardiac allograft rejection requires host, but not donor, expression of B7-1/B7-2 costimulatory molecules. However, acute cardiac rejection requires direct antigen presentation by donor-derived antigen presenting cells to CD4 T-cells and does not require indirect antigen presentation to CD4 T-cells. Given this discrepancy in the literature and that the consequence of allograft exposure in B7-deficient mice is unknown; the goal of the study was to examine the antidonor status of allografted B7-1/B7-2-deficient hosts. METHODS: C57Bl/6 B7-1/B7-2-/- mice were grafted with heterotopic BALB/c hearts. Recipients bearing long-term surviving allografts were used to examine the status of antidonor reactivity in vitro and in vivo. Tolerance was examined in vivo through adoptive transfer of splenocytes from graft-bearing animals to secondary immune-deficient Rag-1-/- hosts bearing donor-type or third-party cardiac allografts and by regulatory T-cell depletion with anti-CD25 antibody. RESULTS: When transferred to B7-replete Rag-1-/- recipients, cells from naïve B7-1/B7-2-/- mice readily initiated cardiac allograft rejection. However, splenocytes transferred from long-term allograft acceptor B7-1/B7-2-/- hosts failed to reject donor-type hearts but acutely rejected third-party allografts. In addition, such cells did not reject (donorxthird-party) F1 allografts. Finally, in vivo depletion of regulatory T-cells did not prevent long-term acceptance. CONCLUSIONS: Results demonstrate that B7-deficient T-cells are capable of acute cardiac allograft rejection in a B7-replete environment. Importantly, results also show that B7-deficient hosts do not simply ignore cardiac allografts, but rather spontaneously develop transferable, donor-specific tolerance and linked suppression in vivo. Interestingly, this tolerant state does not require endogenous CD4+CD25+ regulatory T-cells.
BACKGROUND: Acute cardiac allograft rejection requires host, but not donor, expression of B7-1/B7-2 costimulatory molecules. However, acute cardiac rejection requires direct antigen presentation by donor-derived antigen presenting cells to CD4 T-cells and does not require indirect antigen presentation to CD4 T-cells. Given this discrepancy in the literature and that the consequence of allograft exposure in B7-deficient mice is unknown; the goal of the study was to examine the antidonor status of allografted B7-1/B7-2-deficient hosts. METHODS: C57Bl/6 B7-1/B7-2-/- mice were grafted with heterotopic BALB/c hearts. Recipients bearing long-term surviving allografts were used to examine the status of antidonor reactivity in vitro and in vivo. Tolerance was examined in vivo through adoptive transfer of splenocytes from graft-bearing animals to secondary immune-deficient Rag-1-/- hosts bearing donor-type or third-party cardiac allografts and by regulatory T-cell depletion with anti-CD25 antibody. RESULTS: When transferred to B7-replete Rag-1-/- recipients, cells from naïve B7-1/B7-2-/- mice readily initiated cardiac allograft rejection. However, splenocytes transferred from long-term allograft acceptor B7-1/B7-2-/- hosts failed to reject donor-type hearts but acutely rejected third-party allografts. In addition, such cells did not reject (donorxthird-party) F1 allografts. Finally, in vivo depletion of regulatory T-cells did not prevent long-term acceptance. CONCLUSIONS: Results demonstrate that B7-deficient T-cells are capable of acute cardiac allograft rejection in a B7-replete environment. Importantly, results also show that B7-deficient hosts do not simply ignore cardiac allografts, but rather spontaneously develop transferable, donor-specific tolerance and linked suppression in vivo. Interestingly, this tolerant state does not require endogenous CD4+CD25+ regulatory T-cells.
Authors: Todd J Grazia; Biagio A Pietra; Zachary A Johnson; Brian P Kelly; Robert J Plenter; Ronald G Gill Journal: J Immunol Date: 2004-06-15 Impact factor: 5.422
Authors: F Borriello; M P Sethna; S D Boyd; A N Schweitzer; E A Tivol; D Jacoby; T B Strom; E M Simpson; G J Freeman; A H Sharpe Journal: Immunity Date: 1997-03 Impact factor: 31.745
Authors: G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler Journal: Science Date: 1993-11-05 Impact factor: 47.728
Authors: Hélène Bour-Jordan; Benoît L Salomon; Heather L Thompson; Gregory L Szot; Matthew R Bernhard; Jeffrey A Bluestone Journal: J Clin Invest Date: 2004-10 Impact factor: 14.808
Authors: C G Orosz; E Wakely; S D Bergese; A M VanBuskirk; R M Ferguson; D Mullet; G Apseloff; N Gerber Journal: Transplantation Date: 1996-03-15 Impact factor: 4.939
Authors: T J Grazia; R J Plenter; H M Lepper; F Victorino; S D Miyamoto; J T Crossno; B A Pietra; R G Gill; M R Zamora Journal: Am J Transplant Date: 2010-11-29 Impact factor: 8.086
Authors: Robert J Plenter; Todd J Grazia; Marilyne G Coulombe; Michelle K Nelsen; Christine M Lin; K Scott Beard; Tinalyn M Kupfer; Martin R Zamora; Ronald G Gill; Biagio A Pietra Journal: Cell Immunol Date: 2018-08-07 Impact factor: 4.868